Acorda discontinues PD candidate Tozadenant

Acorda Therapeutics Inc. (NASDAQ: ACOR) discontinued development of Parkinson's disease candidate tozadenant (SYN115) "based on new information" related to cases of agranulocytosis disclosed on Nov. 15 that were possibly related to tozadenant and

Read the full 335 word article

User Sign In